Publisher
Springer Nature Singapore
Reference67 articles.
1. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Bachert***Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133–41. https://doi.org/10.1016/j.jaci.2006.05.031.
2. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet (London). 2019;394(10209):1638–50. https://doi.org/10.1016/s0140-6736(19)31881-1.
3. A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps—Full text view—ClinicalTrials.gov. Retrieved April 19, 2020, from https://clinicaltrials.gov/ct2/show/NCT03280550.
4. Gevaert PO, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Efficacy and safety of omalizumab in patients with chronic rhinosinusitis with nasal polyposis: results from two, multicenter, randomized, double-blind, placebo-controlled phase III trials (POLYP 1 and POLYP 2). J Allergy Clin Immunol Pract. 2020;146(3):595–605.
5. An extension study of omalizumab in participants with chronic rhinosinusitis with nasal polyps—Full text view—ClinicalTrials.gov. Retrieved April 19, 2020, from https://clinicaltrials.gov/ct2/show/NCT03478930.